Nathalie Goemans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nathalie Goemans has a total of 336 co-authors. Here are the top co-authors by number of shared publications:
- Eugenio Mercuri
Pediatric Neurology Unit Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy
8 shared publications - Erik Harmen Niks
Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands
7 shared publications - Francesco Muntoni
Dubowitz Neuromuscular Centre UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital London UK
7 shared publications Eugenio Mercuri
Affiliations Paediatric Neurology, Catholic University, Rome, Italy, Centro Clinico Nemo, Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
6 shared publications- Craig M. McDonald
University of California Davis Health, Sacramento, USA
5 shared publications Gunnar Buyse
University Hospitals Leuven, Leuven, Belgium
5 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e214705
A Validated Prognostic Score for Time to Loss of Ambulation in Patients With Duchenne Muscular Dystrophy
Development of a prognostic score for time to loss of ambulation (LoA) may help guide treatment of patients with Duchenne muscular dystrophy (DMD). Information from clinical data sources was used to create a prognostic score for LoA for use in practice. Data used included 4 natural history databases and 3 clinical trial placebo arms. Inclusion criteria were as follows: (1) 6-minute walk distance ≥75 m; (2) a subsequent visit with an outcome assessment that identified LoA; (3) current corticosteroid use; and (4) available data on prognostic factors. Classification and regression tree models for time to LoA were used to classify patients into 5 risk groups (group 5 = highest risk), prioritizing the easily obtained rise from floor (RFF) and 10-m walk/run (10MWR) times as predictors. The prognostic score was validated in the Cooperative International Neuromuscular Research Group data. Data from 608 boys were analyzed (mean age 9.1 years). Kaplan-Meier curves for time to LoA for each risk group were well separated, describing meaningful differences in time to LoA. Median time to LoA for risk group 1 was not reached during a median of 2.0 years of follow-up. Median times to LoA for risk groups 2-5 were 4.4 (95% CI 4.0-inf), 3.0 (2.1-4.1), 2.0 (1.6-2.1), and 0.9 (0.8-1.6) years, respectively. These risk groups showed concordant times to LoA among 226 patients in the validation data and provided finer separation of patients across different levels of LoA risk than thresholds based on individual functional tests. Patients with DMD were classified into 5 risk groups for LoA using a simple, easy-to-use prognostic score based on RFF and 10MWR thresholds. The prognostic score replicated well in validation data and performed better than previously proposed classifications used in practice. Incorporating the prognostic score for time to LoA into a clinical visit may allow clinicians to counsel patients on trial eligibility, need for mobility devices, home adjustments, financial accommodations, and psychosocial needs. The prognostic score may also be used in trials to inform inclusion criteria and stratification. Study limitations included limited data for prediction of LoA risk beyond 4 years.
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e214705
Open AccessA Validated Prognostic Score for Time to Loss of Ambulation in Patients With Duchenne Muscular Dystrophy
Development of a prognostic score for time to loss of ambulation (LoA) may help guide treatment of patients with Duchenne muscular dystrophy (DMD). Information from clinical data sources was used to create a prognostic score for LoA for use in practice. Data used included 4 natural history databases and 3 clinical trial placebo arms. Inclusion criteria were as follows: (1) 6-minute walk distance ≥75 m; (2) a subsequent visit with an outcome assessment that identified LoA; (3) current corticosteroid use; and (4) available data on prognostic factors. Classification and regression tree models for time to LoA were used to classify patients into 5 risk groups (group 5 = highest risk), prioritizing the easily obtained rise from floor (RFF) and 10-m walk/run (10MWR) times as predictors. The prognostic score was validated in the Cooperative International Neuromuscular Research Group data. Data from 608 boys were analyzed (mean age 9.1 years). Kaplan-Meier curves for time to LoA for each risk group were well separated, describing meaningful differences in time to LoA. Median time to LoA for risk group 1 was not reached during a median of 2.0 years of follow-up. Median times to LoA for risk groups 2-5 were 4.4 (95% CI 4.0-inf), 3.0 (2.1-4.1), 2.0 (1.6-2.1), and 0.9 (0.8-1.6) years, respectively. These risk groups showed concordant times to LoA among 226 patients in the validation data and provided finer separation of patients across different levels of LoA risk than thresholds based on individual functional tests. Patients with DMD were classified into 5 risk groups for LoA using a simple, easy-to-use prognostic score based on RFF and 10MWR thresholds. The prognostic score replicated well in validation data and performed better than previously proposed classifications used in practice. Incorporating the prognostic score for time to LoA into a clinical visit may allow clinicians to counsel patients on trial eligibility, need for mobility devices, home adjustments, financial accommodations, and psychosocial needs. The prognostic score may also be used in trials to inform inclusion criteria and stratification. Study limitations included limited data for prediction of LoA risk beyond 4 years.
- Open Access
- 1 October 2025
- Published by Springer Nature in Journal of NeuroEngineering and Rehabilitation
- Vol. 22 (1) , 1-15
Longitudinal interaction between muscle impairments and gait pathology in growing children with Duchenne muscular dystrophy
Children with Duchenne muscular dystrophy (DMD) present with progressive gait pathology due to progressive muscle weakness and contractures. However, the associations between specific muscle impairments and specific gait features have never been quantified. Therefore, the aim of this longitudinal observational cohort study was to investigate the longitudinal interaction between progressive muscle impairments and progressive gait pathology in growing boys with DMD. Thirty-one boys with DMD (aged 4.6–16.4 years) were repeatedly measured between 2015 and 2022, resulting in a total dataset of 152 observations. Fixed dynamometry, goniometry and 3D gait analysis were used to assess lower limb muscle weakness, passive range of motion and gait. Joint random-effect models between gait and muscle outcomes were fitted. The correlation between the random intercepts (ra) and random slopes (rb) indicated the relationship between the initial values and progression rates over time of two outcomes, respectively. Specific muscle impairments were related to specific gait features, both in terms of initial values (ra=0.470–0.757; p < 0.029) and progression rates (rb=0.547–0.812; p < 0.024). Decreased hip extension strength was associated with increased maximal posterior trunk angle (rb=-0.588; p = 0.0004), increased maximal anterior pelvic tilt angle (ra=-0.543; p = 0.0040 and rb=-0.812; p < 0.0001), and reduced maximal hip extension moment (ra=0.536; p = 0.0289). Decreased hip abduction strength was associated with increased step width (ra=-0.549; p = 0.0021) and increased maximal internal foot progression angle (rb=-0.547; p = 0.0117). Decreased knee extension strength was associated with reduced maximal knee extension moment (ra=0.702; p < 0.0001), reduced maximal knee power absorption (ra=0.757; p < 0.0001), and reduced dorsiflexion angle at initial contact (rb=0.684; p = 0.0237). Decreased dorsiflexion range of motion was associated with reduced dorsiflexion angle at initial contact (ra=0.732; p < 0.0001 and rb=0.627; p = 0.0202) and reduced maximal dorsiflexion angle in swing (ra=0.663; p < 0.0001). This is the first study that objectively quantified the longitudinal interaction between muscle impairments and gait features, providing valuable insights into the underlying mechanisms of pathological gait in DMD. The observed associations highlight the importance of targeted clinical assessments. These findings offer a foundation for optimizing rehabilitation strategies, orthotic management, and orthopedic interventions, ultimately improving clinical decision-making and enhancing mobility outcomes in children with DMD.
- 1 October 2025
- Published by Springer Nature in Journal of NeuroEngineering and Rehabilitation
- Vol. 22 (1) , 1-15
Open AccessLongitudinal interaction between muscle impairments and gait pathology in growing children with Duchenne muscular dystrophy
Children with Duchenne muscular dystrophy (DMD) present with progressive gait pathology due to progressive muscle weakness and contractures. However, the associations between specific muscle impairments and specific gait features have never been quantified. Therefore, the aim of this longitudinal observational cohort study was to investigate the longitudinal interaction between progressive muscle impairments and progressive gait pathology in growing boys with DMD. Thirty-one boys with DMD (aged 4.6–16.4 years) were repeatedly measured between 2015 and 2022, resulting in a total dataset of 152 observations. Fixed dynamometry, goniometry and 3D gait analysis were used to assess lower limb muscle weakness, passive range of motion and gait. Joint random-effect models between gait and muscle outcomes were fitted. The correlation between the random intercepts (ra) and random slopes (rb) indicated the relationship between the initial values and progression rates over time of two outcomes, respectively. Specific muscle impairments were related to specific gait features, both in terms of initial values (ra=0.470–0.757; p < 0.029) and progression rates (rb=0.547–0.812; p < 0.024). Decreased hip extension strength was associated with increased maximal posterior trunk angle (rb=-0.588; p = 0.0004), increased maximal anterior pelvic tilt angle (ra=-0.543; p = 0.0040 and rb=-0.812; p < 0.0001), and reduced maximal hip extension moment (ra=0.536; p = 0.0289). Decreased hip abduction strength was associated with increased step width (ra=-0.549; p = 0.0021) and increased maximal internal foot progression angle (rb=-0.547; p = 0.0117). Decreased knee extension strength was associated with reduced maximal knee extension moment (ra=0.702; p < 0.0001), reduced maximal knee power absorption (ra=0.757; p < 0.0001), and reduced dorsiflexion angle at initial contact (rb=0.684; p = 0.0237). Decreased dorsiflexion range of motion was associated with reduced dorsiflexion angle at initial contact (ra=0.732; p < 0.0001 and rb=0.627; p = 0.0202) and reduced maximal dorsiflexion angle in swing (ra=0.663; p < 0.0001). This is the first study that objectively quantified the longitudinal interaction between muscle impairments and gait features, providing valuable insights into the underlying mechanisms of pathological gait in DMD. The observed associations highlight the importance of targeted clinical assessments. These findings offer a foundation for optimizing rehabilitation strategies, orthotic management, and orthopedic interventions, ultimately improving clinical decision-making and enhancing mobility outcomes in children with DMD.
- Open Access
- 27 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0325736
Predicting trajectories of the north star ambulatory assessment total score in Duchenne muscular dystrophy
The North Star Ambulatory Assessment (NSAA) is a widely used functional endpoint in drug development for ambulatory patients with Duchenne muscular dystrophy (DMD). Accurately predicting NSAA total score trajectories is important for designing randomized trials for novel therapies in DMD and for contextualizing outcomes, especially over longer-term follow-up (>18 months) when placebo-controlled studies are infeasible. We developed a prognostic model for NSAA total score trajectories over at most 5 years of follow-up for patients with DMD aged 4 to DMD genotype class, index year, and data source. Among N = 416 patients at baseline, mean age was 8.2 years, mean NSAA total score was 24, and 61% were receiving prednisone and 39% deflazacort, with the majority having been treated with daily corticosteroid regimens (69%) relative to other regimens (31%). Patients had an average of four NSAA assessments post-baseline during a median follow-up of 2.6 years (inter-quartile range 1.9 to 3.6 years). The best-fitting model in the full study sample explained 39% of the variation in NSAA total score changes, with prediction errors of ±3.6, 5.1, 5.9, 7.5, 9.5 NSAA units during follow-up years 1–5, respectively. The most important predictors were baseline age, NSAA, rise from floor velocity, and 10-meter walk/run velocity. In conclusion, trajectories of ambulatory motor function in DMD, as measured by the NSAA total score, can be well-predicted using readily available baseline characteristics. We discuss applications of these predictions to DMD drug development.
- 27 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0325736
Open AccessPredicting trajectories of the north star ambulatory assessment total score in Duchenne muscular dystrophy
The North Star Ambulatory Assessment (NSAA) is a widely used functional endpoint in drug development for ambulatory patients with Duchenne muscular dystrophy (DMD). Accurately predicting NSAA total score trajectories is important for designing randomized trials for novel therapies in DMD and for contextualizing outcomes, especially over longer-term follow-up (>18 months) when placebo-controlled studies are infeasible. We developed a prognostic model for NSAA total score trajectories over at most 5 years of follow-up for patients with DMD aged 4 to DMD genotype class, index year, and data source. Among N = 416 patients at baseline, mean age was 8.2 years, mean NSAA total score was 24, and 61% were receiving prednisone and 39% deflazacort, with the majority having been treated with daily corticosteroid regimens (69%) relative to other regimens (31%). Patients had an average of four NSAA assessments post-baseline during a median follow-up of 2.6 years (inter-quartile range 1.9 to 3.6 years). The best-fitting model in the full study sample explained 39% of the variation in NSAA total score changes, with prediction errors of ±3.6, 5.1, 5.9, 7.5, 9.5 NSAA units during follow-up years 1–5, respectively. The most important predictors were baseline age, NSAA, rise from floor velocity, and 10-meter walk/run velocity. In conclusion, trajectories of ambulatory motor function in DMD, as measured by the NSAA total score, can be well-predicted using readily available baseline characteristics. We discuss applications of these predictions to DMD drug development.
- Open Access
Longitudinal interaction between muscle impairments and gait pathology in growing children with Duchenne muscular dystrophy
Aim: The aim of this longitudinal observational cohort study was to investigate the longitudinal interaction between progressive muscle impairments and progressive gait pathology in growing boys with Duchenne muscular dystrophy (DMD). Methods: Thirty-one boys with DMD (aged 4y7mo-16y5mo), were repeatedly measured between 2015 and 2022, resulting in a total dataset of 152 observations. Fixed dynamometry, goniometry and 3D gait analysis were used to asses lower limb muscle weakness, passive range of motion and gait. Joint random-effects models between gait and muscle impairment outcomes were fitted. The correlation between the random intercepts ( r a ) and random slopes ( r b ) indicated the degree to which respectively the starting levels and progression rates over time of two outcomes were related in boys with DMD. Results: Specific muscle impairments were related to specific gait features, in terms of starting levels ( r a =0.470-0.757; p r b =0.547-0.812; p<0.024). Interpretation: The findings improved insights into how specific muscle impairments may contribute to specific gait features in DMD. This could enhance clinical decision making, advance rehabilitation, orthotic and orthopedic interventions, and reveal sensitive outcome measures to prove the efficacy of novel treatments in clinical trials. What this paper adds: Objective quantification of the relationships between muscle impairments and gait features Relationships between starting levels of specific muscle impairments and specific gait features Relationships between progression rates of specific muscle impairments and specific gait features Improved insights into how muscle impairments may contribute to gait features
Open AccessLongitudinal interaction between muscle impairments and gait pathology in growing children with Duchenne muscular dystrophy
Aim: The aim of this longitudinal observational cohort study was to investigate the longitudinal interaction between progressive muscle impairments and progressive gait pathology in growing boys with Duchenne muscular dystrophy (DMD). Methods: Thirty-one boys with DMD (aged 4y7mo-16y5mo), were repeatedly measured between 2015 and 2022, resulting in a total dataset of 152 observations. Fixed dynamometry, goniometry and 3D gait analysis were used to asses lower limb muscle weakness, passive range of motion and gait. Joint random-effects models between gait and muscle impairment outcomes were fitted. The correlation between the random intercepts ( r a ) and random slopes ( r b ) indicated the degree to which respectively the starting levels and progression rates over time of two outcomes were related in boys with DMD. Results: Specific muscle impairments were related to specific gait features, in terms of starting levels ( r a =0.470-0.757; p r b =0.547-0.812; p<0.024). Interpretation: The findings improved insights into how specific muscle impairments may contribute to specific gait features in DMD. This could enhance clinical decision making, advance rehabilitation, orthotic and orthopedic interventions, and reveal sensitive outcome measures to prove the efficacy of novel treatments in clinical trials. What this paper adds: Objective quantification of the relationships between muscle impairments and gait features Relationships between starting levels of specific muscle impairments and specific gait features Relationships between progression rates of specific muscle impairments and specific gait features Improved insights into how muscle impairments may contribute to gait features
- Open Access
- 30 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0307118
Characterization of patients with Duchenne muscular dystrophy across previously developed health states
Project HERCULES has developed a natural history model (NHM) of disease progression in Duchenne muscular dystrophy (DMD) that comprises eight ordered health states (two ambulatory states, one transfer state indicating increased caregiver burden in which patients cannot walk/run 10m or rise from floor but can still support their own weight, and five non-ambulatory states). The current study used data from nine sources (clinical trial placebo arms, one real-world dataset, and three natural history datasets) to further characterize patients with DMD according to these health states. The study included 1,173 patients across 5,306 visits. Patients were on average older and exhibited worse ambulatory, pulmonary, upper limb, and cardiac functions with each successive health state. Mean±SE ages increased monotonically across health states, starting with 8.47±0.07 for early ambulatory, 10.86±0.13 for late ambulatory, 11.65±0.35 for transfer state, and ranging from 13.17±0.32 to 16.84±0.37 for the non-ambulatory states. North Star Ambulatory Assessment (NSAA) total score, which measures motor function and ranges from 34 (best) to 0 (worst), was 23.7 (interquartile range [IQR]: 20–30) for early ambulatory patients, 12.7 (IQR: 9–16) for late ambulatory patients, and 3.9 (IQR: 2–5) for transfer patients. Pulmonary function as measured by mean±SE of forced vital capacity percent predicted (FVC%p) was 94.5±0.8 for early ambulatory, 89.1±1.4 for late ambulatory, and 80.2±2.8 for transfer states, and decreased from 77.2±1.7 to 20.6±1.6 across the five non-ambulatory health states. In summary, these findings further characterize health states and their interpretation in economic modeling and decision-making in DMD management.
- 30 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0307118
Open AccessCharacterization of patients with Duchenne muscular dystrophy across previously developed health states
Project HERCULES has developed a natural history model (NHM) of disease progression in Duchenne muscular dystrophy (DMD) that comprises eight ordered health states (two ambulatory states, one transfer state indicating increased caregiver burden in which patients cannot walk/run 10m or rise from floor but can still support their own weight, and five non-ambulatory states). The current study used data from nine sources (clinical trial placebo arms, one real-world dataset, and three natural history datasets) to further characterize patients with DMD according to these health states. The study included 1,173 patients across 5,306 visits. Patients were on average older and exhibited worse ambulatory, pulmonary, upper limb, and cardiac functions with each successive health state. Mean±SE ages increased monotonically across health states, starting with 8.47±0.07 for early ambulatory, 10.86±0.13 for late ambulatory, 11.65±0.35 for transfer state, and ranging from 13.17±0.32 to 16.84±0.37 for the non-ambulatory states. North Star Ambulatory Assessment (NSAA) total score, which measures motor function and ranges from 34 (best) to 0 (worst), was 23.7 (interquartile range [IQR]: 20–30) for early ambulatory patients, 12.7 (IQR: 9–16) for late ambulatory patients, and 3.9 (IQR: 2–5) for transfer patients. Pulmonary function as measured by mean±SE of forced vital capacity percent predicted (FVC%p) was 94.5±0.8 for early ambulatory, 89.1±1.4 for late ambulatory, and 80.2±2.8 for transfer states, and decreased from 77.2±1.7 to 20.6±1.6 across the five non-ambulatory health states. In summary, these findings further characterize health states and their interpretation in economic modeling and decision-making in DMD management.
- 27 September 2024
- Published by Elsevier in Research in Developmental Disabilities
- Vol. 154, 104845
How do fine and gross motor skills develop in preschool boys with Duchenne Muscular Dystrophy?
- 27 September 2024
- Published by Elsevier in Research in Developmental Disabilities
- Vol. 154, 104845
How do fine and gross motor skills develop in preschool boys with Duchenne Muscular Dystrophy?
- Open Access
- 10 July 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (7) , e0304984
Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study
Evaluations of treatment efficacy in Duchenne muscular dystrophy (DMD), a rare genetic disease that results in progressive muscle wasting, require an understanding of the ‘meaningfulness’ of changes in functional measures. We estimated the minimal detectable change (MDC) for selected motor function measures in ambulatory DMD, i.e., the minimal degree of measured change needed to be confident that true underlying change has occurred rather than transient variation or measurement error. MDC estimates were compared across multiple data sources, representing >1000 DMD patients in clinical trials and real-world clinical practice settings. Included patients were ambulatory, aged ≥4 to 80% confidence in true change were 2.8 units for the North Star Ambulatory Assessment (NSAA) total score, 1.3 seconds for the 4-stair climb (4SC) completion time, 0.36 stairs/second for 4SC velocity and 36.3 meters for the 6-minute walk distance (6MWD). MDC estimates were similar across clinical trial and real-world data sources, and tended to be slightly larger than MCIDs for these measures. The identified thresholds can be used to inform endpoint definitions, or as benchmarks for monitoring individual changes in motor function in ambulatory DMD.
- 10 July 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (7) , e0304984
Open AccessMeaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study
Evaluations of treatment efficacy in Duchenne muscular dystrophy (DMD), a rare genetic disease that results in progressive muscle wasting, require an understanding of the ‘meaningfulness’ of changes in functional measures. We estimated the minimal detectable change (MDC) for selected motor function measures in ambulatory DMD, i.e., the minimal degree of measured change needed to be confident that true underlying change has occurred rather than transient variation or measurement error. MDC estimates were compared across multiple data sources, representing >1000 DMD patients in clinical trials and real-world clinical practice settings. Included patients were ambulatory, aged ≥4 to 80% confidence in true change were 2.8 units for the North Star Ambulatory Assessment (NSAA) total score, 1.3 seconds for the 4-stair climb (4SC) completion time, 0.36 stairs/second for 4SC velocity and 36.3 meters for the 6-minute walk distance (6MWD). MDC estimates were similar across clinical trial and real-world data sources, and tended to be slightly larger than MCIDs for these measures. The identified thresholds can be used to inform endpoint definitions, or as benchmarks for monitoring individual changes in motor function in ambulatory DMD.
- Open Access
- 9 May 2024
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 11 (4) , 801-814
Development and Pilot Validation of the DuMAND Checklist to Screen for Duchenne Muscular Dystrophy-Associated Neurobehavioral Difficulties (DuMAND)
Background: Patients with Duchenne muscular dystrophy (DMD) face a higher risk of neurobehavioral problems, yet an international consensus on screening, assessing, and managing these difficulties is lacking. Objective: This report introduces the term Duchenne Muscular Dystrophy-Associated Neurobehavioral Difficulties (DuMAND) to comprehensively cover the spectrum of neurobehavioral issues in DMD patients, including behavior, psychiatric disorders, and various cognitive, academic, and psychosocial deficits. To facilitate screening, the DuMAND Checklist, a 43-item tool with five subscales, was developed. Methods and results: DuMAND categories were derived through literature review, parent (48 mothers and 37 fathers), and expert ( n = 28) input and feedback. The DuMAND Checklist subscales were developed iteratively, incorporating item selection, expert panel ( n = 10) assessment for face validity, comprehensiveness, and a pilot validation study in a DMD sample ( n = 20). DuMAND encompasses five categories: cognition and learning, social responsiveness, emotion regulation, externalizing behavior, and eating and sleeping. Preliminary validation of the DuMAND Checklist indicates acceptable-to-excellent internal consistency and construct validity. Conclusion: By introducing the DuMAND concept, this study seeks to inspire a consensus approach for screening, assessing, and managing neurobehavioral issues in DMD. Incorporating screening, using the DuMAND Checklist, in addition to medical follow-up will facilitate early intervention, addressing a critical gap in identification of neurobehavioral disorders in DMD. Future research is needed to further evaluate psychometric properties of the DuMAND Checklist and investigate the natural course of DuMAND.
- 9 May 2024
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 11 (4) , 801-814
Open AccessDevelopment and Pilot Validation of the DuMAND Checklist to Screen for Duchenne Muscular Dystrophy-Associated Neurobehavioral Difficulties (DuMAND)
Background: Patients with Duchenne muscular dystrophy (DMD) face a higher risk of neurobehavioral problems, yet an international consensus on screening, assessing, and managing these difficulties is lacking. Objective: This report introduces the term Duchenne Muscular Dystrophy-Associated Neurobehavioral Difficulties (DuMAND) to comprehensively cover the spectrum of neurobehavioral issues in DMD patients, including behavior, psychiatric disorders, and various cognitive, academic, and psychosocial deficits. To facilitate screening, the DuMAND Checklist, a 43-item tool with five subscales, was developed. Methods and results: DuMAND categories were derived through literature review, parent (48 mothers and 37 fathers), and expert ( n = 28) input and feedback. The DuMAND Checklist subscales were developed iteratively, incorporating item selection, expert panel ( n = 10) assessment for face validity, comprehensiveness, and a pilot validation study in a DMD sample ( n = 20). DuMAND encompasses five categories: cognition and learning, social responsiveness, emotion regulation, externalizing behavior, and eating and sleeping. Preliminary validation of the DuMAND Checklist indicates acceptable-to-excellent internal consistency and construct validity. Conclusion: By introducing the DuMAND concept, this study seeks to inspire a consensus approach for screening, assessing, and managing neurobehavioral issues in DMD. Incorporating screening, using the DuMAND Checklist, in addition to medical follow-up will facilitate early intervention, addressing a critical gap in identification of neurobehavioral disorders in DMD. Future research is needed to further evaluate psychometric properties of the DuMAND Checklist and investigate the natural course of DuMAND.
- Open Access
- 29 April 2024
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 11 (4) , 791-799
Duchenne Muscular Dystrophy-Associated Neurobehavioral Difficulties: Insights from Clinical Practice
Background: Emerging evidence underscores the high prevalence of neurobehavioral difficulties like ADHD, ASD and OCD, in patients with Duchenne muscular dystrophy (DMD). The substantial impact of these complex behavioral challenges in addition to motor function decline on the well-being of affected individuals and their families is increasingly evident. However, a uniform approach for effective screening, assessment and management of the neurobehavioral symptoms remains elusive. Objective: We explored strategies used by healthcare professionals with clinical expertise in DMD to address neurobehavioral symptoms, in order to uncover diverse practices and to identify potential directions for clinical approaches in managing DMD neurobehavioral symptoms. Methods and results: Twenty-eight respondents from 16 different countries completed an online survey. Only 35% of the centers systematically screened for neurobehavioral difficulties in their DMD population. Predominant screening methods included history taking and clinical observation. Common neurobehavioral difficulties encompassed learning challenges, dependency from adults, anxiety, concentration difficulties, and social deficits. The participating centers frequently employed parental counseling and liaison with psychosocial healthcare professionals for psychosocial intervention. Conclusion: This study underscores the complex behavioral landscape in DMD, highlighting the need for validated screening, assessment and management strategies and collaborative efforts in implementing these. We advocate for international consensus recommendations for screening, assessment and management of neurobehavioral difficulties in DMD to enhance patient care and communication across healthcare settings.
- 29 April 2024
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 11 (4) , 791-799
Open AccessDuchenne Muscular Dystrophy-Associated Neurobehavioral Difficulties: Insights from Clinical Practice
Background: Emerging evidence underscores the high prevalence of neurobehavioral difficulties like ADHD, ASD and OCD, in patients with Duchenne muscular dystrophy (DMD). The substantial impact of these complex behavioral challenges in addition to motor function decline on the well-being of affected individuals and their families is increasingly evident. However, a uniform approach for effective screening, assessment and management of the neurobehavioral symptoms remains elusive. Objective: We explored strategies used by healthcare professionals with clinical expertise in DMD to address neurobehavioral symptoms, in order to uncover diverse practices and to identify potential directions for clinical approaches in managing DMD neurobehavioral symptoms. Methods and results: Twenty-eight respondents from 16 different countries completed an online survey. Only 35% of the centers systematically screened for neurobehavioral difficulties in their DMD population. Predominant screening methods included history taking and clinical observation. Common neurobehavioral difficulties encompassed learning challenges, dependency from adults, anxiety, concentration difficulties, and social deficits. The participating centers frequently employed parental counseling and liaison with psychosocial healthcare professionals for psychosocial intervention. Conclusion: This study underscores the complex behavioral landscape in DMD, highlighting the need for validated screening, assessment and management strategies and collaborative efforts in implementing these. We advocate for international consensus recommendations for screening, assessment and management of neurobehavioral difficulties in DMD to enhance patient care and communication across healthcare settings.
- Top Cited PapersOpen Access
- 12 March 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (5) , e208112
Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy
Background and ObjectivesVamorolone is a dissociative agonist of the glucocorticoid receptor that has shown similar efficacy and reduced safety concerns in comparison with prednisone in Duchenne muscular dystrophy (DMD). This study was conducted to ...
- 12 March 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (5) , e208112
Top Cited PapersOpen AccessEfficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy
Background and ObjectivesVamorolone is a dissociative agonist of the glucocorticoid receptor that has shown similar efficacy and reduced safety concerns in comparison with prednisone in Duchenne muscular dystrophy (DMD). This study was conducted to ...